Voyager Therapeutics, Inc.VYGRNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank46
3Y CAGR-61.2%
5Y CAGR-39.6%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
-61.2%/yr
vs -13.7%/yr prior
5Y CAGR
-39.6%/yr
Recent deceleration
Acceleration
-47.6pp
Decelerating
Percentile
P46
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.17% |
| Q3 2025 | 9.05% |
| Q2 2025 | 10.86% |
| Q1 2025 | -162.55% |
| Q4 2024 | 47.98% |
| Q3 2024 | 13.28% |
| Q2 2024 | -157.48% |
| Q1 2024 | 330.99% |
| Q4 2023 | -12.28% |
| Q3 2023 | -967.63% |
| Q2 2023 | -101.66% |
| Q1 2023 | 1033.87% |
| Q4 2022 | 20.06% |
| Q3 2022 | 16.44% |
| Q2 2022 | -157.37% |
| Q1 2022 | 217.00% |
| Q4 2021 | 150.77% |
| Q3 2021 | 6.86% |
| Q2 2021 | -5.88% |
| Q1 2021 | 15.13% |
| Q4 2020 | 14.58% |
| Q3 2020 | -29.50% |
| Q2 2020 | 23.83% |
| Q1 2020 | -13.35% |
| Q4 2019 | -17.51% |
| Q3 2019 | 32.33% |
| Q2 2019 | -127.10% |
| Q1 2019 | 598.81% |
| Q4 2018 | -34.47% |
| Q3 2018 | 22.38% |
| Q2 2018 | -150.69% |
| Q1 2018 | 413.46% |
| Q4 2017 | 8.00% |
| Q3 2017 | 2.99% |
| Q2 2017 | 2.53% |
| Q1 2017 | -1.64% |
| Q4 2016 | -58.63% |
| Q3 2016 | -7.88% |
| Q2 2016 | 0.36% |
| Q1 2016 | -2.78% |